Authors: Safra, T Groshen, S Jeffers, S Tsao-Wei, DD Zhou, LY Muderspach, L Roman, L Morrow, CP Burnett, A Muggia, FM

Citation: T. Safra et al., Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin - Analysis of toxicities and predictors of outcome, CANC CYTOP, 91(1), 2001, pp. 90-100

Authors: Safra, T Groshen, S Jeffers, S Tsao-Wei, DD Zhou, LY Muderspach, L Roman, L Morrow, CP Burnett, A Muggia, FM

Citation: T. Safra et al., Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin - Analysis of toxicities and predictors of outcome, CANCER, 91(1), 2001, pp. 90-100

Authors: Safra, T Muggia, F Jeffers, S Tsao-Wei, DD Groshen, S Lyass, O Henderson, R Berry, G Gabizon, A

Citation: T. Safra et al., Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m(2), ANN ONCOL, 11(8), 2000, pp. 1029-1033

Authors: Muggia, FM Safra, T Jeffers, S Garcia, A Groshen, S

Citation: Fm. Muggia et al., Intraperitoneal therapy with fluoropyrimidines in the treatment of ovarianand gastrointestinal cancers, CUR CLIN ON, 2, 2000, pp. 213-223

Authors: Freier, S Weiss, O Eran, M Flyvbjerg, A Dahan, R Nephesh, I Safra, T Shiloni, E Raz, I

Citation: S. Freier et al., Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon, GUT, 44(5), 1999, pp. 704-708